<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11104552</article-id><article-id pub-id-type="pmc">2363467</article-id><article-id pub-id-type="pii">6691503</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1503</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cheeseman</surname><given-names>S L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Brannan</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>McGown</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Khan</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gardner</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Gumbrell</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Dickens</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ranson</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester</aff><aff id="aff2"><label>2</label>Clinical Pharmacology, Cell Therapeutics Inc, Seattle, WA</aff><aff id="aff3"><label>3</label>CRC Section of Drug Development and Imaging, Paterson Institute for Cancer Research, Wilmslow Road, Manchester, M20 4BX</aff><aff id="aff4"><label>4</label>Cancer Research Campaign, 10 Cambridge Terrace, London, NW1 4JL, UK</aff><pub-date pub-type="ppub"><month>12</month><year>2000</year></pub-date><volume>83</volume><issue>12</issue><fpage>1599</fpage><lpage>1606</lpage><history><date date-type="received"><day>16</day><month>12</month><year>1999</year></date><date date-type="rev-recd"><day>06</day><month>07</month><year>2000</year></date><date date-type="accepted"><day>09</day><month>08</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>CT-2584 HMS, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine-hydrogen methanesulphonate, is a modulator of intracellular phosphatidic acid. We treated 30 patients as part of a Phase I and pharmacokinetic study to determine the maximum-tolerated dose of CT-2584 HMS, toxicity profiles, pharmacokinetic profile and antitumour effects at escalating dose levels. CT-2584 HMS was given as a continuous infusion for 6 hours for 5 consecutive days every 3 weeks. Plasma samples for pharmacokinetic studies were analysed using a validated high-performance liquid chromatographic assay. Mean C <sub>max</sub> and AUC values for each dose group were similar on days 1 and 5 and increases in plasma concentration (C <sub>max</sub> and AUC) appeared proportional to the dose. CT-2584 HMS had a mean elimination half-life of 7.3 hours. Values of V <sub>d</sub> and clearance were independent of dose and duration of treatment. Dose escalation was halted at 585 mg/m<sup>2</sup> because of malaise and lethargy, which was sometimes accompanied by nausea and headache. 26 patients were evaluable for response, one patient with pleural mesothelioma achieved a partial response to treatment confirmed by CT scanning. A dose level of 520 mg/m<sup>2</sup> daily &#x000d7; 5 days would be suitable for Phase II testing. Alternative schedules of CT-2584 HMS to overcome the limiting toxicity of malaise would be worthy of examination. &#x000a9; 2000 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.org.uk">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>CT-2584 HMS</kwd><kwd>phosphatidic acid</kwd><kwd>Phase I</kwd><kwd>pharmacokinetic</kwd></kwd-group></article-meta></front></article>


